Epitalon
ALSO SOLD AS Epithalon
Last reviewed 2026-10-30
Our read Opinion
Limited human melatonin reports accompany mostly preclinical longevity research. FDA retains safety concerns after nomination withdrawal; robust human longevity evidence is absent.
- Type
- Research-only / unapproved
- Regulatory status
- No FDA approval; foreign authorization unverified
- Compounding status
- Off Category 2, review pending
- FDA-approved indications
- None
- Evidence level
- Small/early human studies
- Routes studied
- Injection
- WADA
- Verify
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to influence aging markers
A synthetic tetrapeptide investigated for effects on telomerase, cellular aging and pineal melatonin regulation. These mechanistic observations do not establish human lifespan extension.
No FDA approval or EMA authorization was identified for synthetic Epitalon. It must not be confused with Epithalamin, a pineal peptide extract used in older studies.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
1 news items in last 30 days
Biomarker changes are not proof of longer life. Claims based on pineal extracts should not be attributed automatically to this synthetic tetrapeptide.
STAT
Reporters examine claims made by clinics promoting epitalon for aging.
Slowing biological aging: telomeres, sleep/circadian rhythm and brain aging.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.